M
ost people who could benefit from substance use disorder (SUD) treatment do not actively seek it (SAMHSA, 2014) . Left untreated, SUDs contribute significantly to mortality (Degenhardt et al., 2011a (Degenhardt et al., , 2011b Scott et al., 2011; Degenhardt et al., 2014) , public health burdens (Degenhardt and Hall, 2012; Degenhardt et al., 2013) , and various economic and societal costs (Mark et al., 2001; Rehm et al., 2009; Birnbaum et al., 2011) . SUDs have a high rate of comorbidity with sexually transmitted diseases (STDs), including HIV/AIDS, syphilis, and chlamydia (Booth et al., 1993; Zenilman et al., 1994; Cook and Clark, 2005; Calsyn et al., 2010; Tetrault et al., 2010; CDC, 2013) . Injection drug use continues to be a risk factor for HIV transmission, and drug use can impair judgment, including increased risk of unsafe sex practices (Ross et al., 2003; Cook and Clark, 2005; Burnette et al., 2008; Reback et al., 2008; Ostrow et al., 2009; CDC, 2013) . Whether by predisposition to risky behaviors, impaired decision-making, disorganization, or direct health effects, substance use can potentially impact the acquisition and clinical prognosis of STDs. Linking individuals with SUDs to treatment can effectively reduce drug use and its attendant problems (Sorensen and Copeland, 2000; Wood et al., 2004; Farrell et al., 2005; Volkow et al., 2011) .
Research shows high rates of SUDs among STD clinic patients. One study with young people ages 15 to 24 years attending an urban STD clinic found that prevalence of SUDs was higher than that of confirmed STDs (Cook et al., 2006) . In the general population, STDs have been found to be associated with alcohol use disorders and marijuana use (Tetrault et al., 2010) . Prior research suggests that screening can effectively identify STD clinic patients with substance use problems, and supports the feasibility of providing interventions for substance use in the STD clinic setting (Appel et al., 2006; Lane et al., 2008; Yu et al., 2008; Appel et al., 2015) . Moreover, there is emerging evidence that providing substance use interventions in STD clinic settings is associated with improved outcomes, including reduced incidence of STD infection detected at subsequent clinic visits (Rogers et al., 2015; Yu et al., 2016) .
The current manuscript reports findings from 2 pilot studies conducted at the 2 Baltimore City Health Department (BCHD) STD clinics. The screening study characterized rates of substance use and SUDs among STD clinic patients. Prior studies have examined substance use and/or its correlates among STD clinic patients using frequency/quantity measures or screening tools (eg, Zenilman et al., 1994; Hutton et al., 2008; Scott-Sheldon et al., 2009; Senn et al., 2010) , but few have specifically assessed SUD criteria among STD clinic patients (eg, Cook et al., 2006 did, for alcohol and marijuana). To our knowledge, this is the first study to characterize SUDs in this population using Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria. The Treatment Linkage Feasibility study examined the feasibility of linking STD clinic patients with opioid and/or cocaine use disorders to SUD treatment in the community using a patient navigation service, for which feasibility and efficacy are unknown in this clinical population. Both of these studies were conducted to inform future research and clinical services in STD clinics.
METHODS
Below we describe the methodology for 2 pilot studies conducted at the 2 public STD clinics in Baltimore, MD. These studies focused on characterizing rates of SUDs among clinic patients (study 1-screening) and linking patients to SUD treatment (study 2-treatment linkage feasibility) ( Table 1) .
The 2 clinics provide walk-in STD testing and treatment (including HIV primary care and pre-exposure prophylaxis [PrEP] ) for city residents. Located in East and West Baltimore, the clinics are open on alternating days, and serve urban, primarily minority populations. Study 1 was conducted at the East Baltimore clinic, whereas study 2 was conducted at both clinic locations. Both studies were approved by the Friends Research Institute's Institutional Review Board and underwent BCHD internal review.
Study 1: Screening

Recruitment
Research staff approached patients in the clinic waiting area and invited them to participate in a health study. Patients who expressed interest were accompanied to a private office in the clinic, where research staff described the study in detail. Because no names or other identifying information were collected as part of this study, written informed consent was not required by the IRB. Researchers obtained verbal consent and provided participants an information sheet. With the goal of recruiting 100 participants, research staff approached 135 patients; 35 declined and the remaining 100 completed a private face-to-face interview. Because patients were approached directly in the waiting area, the 100 participants should be representative of the population of clinic patients who would agree to be interviewed.
Assessment
The interview consisted of selected items from the modified World Mental Health Composite International Diagnostic Interview (WMH CIDI; World Health Organization, 2015) , which map to DSM-5 SUD criteria. An earlier version of the CIDI was widely used to determine SUDs in epidemiological and clinical trials research (Forman et al., 2004) . Consistent with revised criteria from DSM-IV to DSM-5 (Hasin et al., 2013) , a scoring modification involved dropping the legal problems item and adding an item on craving. Our team has used this approach to assess DSM-5 SUDs in various clinical populations (Kelly et al., 2014; Gryczynski et al., 2015; McNeely et al., 2016) . The modified WMH CIDI items query clinically significant problems in the past 12 months based on DSM-5 criteria separately for different substance classes, including alcohol, cannabis, heroin, prescription opioids, cocaine, amphetamines, and sedatives. For prescription medications, participants were explicitly asked to only report nonmedical use, that is, use of medications ''that were not prescribed to you by a doctor, or that you used more than prescribed or for longer than prescribed.'' Participants The STD clinical staff informed patients about a potential health study opportunity, and referred interested patients for screening by research staff, who privately assessed patients for eligibility after their medical visit. Patients were eligible if they were STD clinic patients, aged 18 or older, and met diagnostic criteria for DSM-5 opioid and/or cocaine use disorder (assessed as in study 1). Patients were excluded if they could not understand English, reported no use of opioids or cocaine in the past month, or were unwilling or unable to provide informed consent.
Intervention
Due to resource constraints, we used an abbreviated 1-month form of an intervention model that coupled motivational interviewing techniques (Miller and Rollnick, 2012) to address internal barriers (eg, ambivalence about treatment, low motivation, etc), with Patient Navigation services to address external barriers (eg, disorganization, lack of transportation or insurance, etc). Patient Navigation is a promising strategy utilized to link patients to appropriate outpatient services in the community (Freeman et al., 1995; Gardner et al., 2005; Bradford et al., 2007; Percac-Lima et al., 2009; Freeman and Rodriguez, 2011) . Navigators work with patients to overcome various barriers to care and facilitate access to appropriate services. Table 2 describes the types of barriers that might be encountered and how the Navigator would respond. This patient-centered strategy is fitting to guide low-resource and/or vulnerable populations through the intricacies of the modern healthcare system, and may be particularly well-suited for bridging the gap across the distinct public health sectors of STD clinics and SUD treatment.
The intervention was delivered by a nonclinician but experienced Patient Navigator, who had worked on large clinical trials of Patient Navigation, including a clinical trial with hospitalized HIV patients and an ongoing trial of patient navigation for newly released jail inmates. The Navigator's role on those studies included specialized training and supervision in case management and motivational interviewing.
In the initial session, the Navigator gauged participants' readiness for SUD treatment and explored each participants' specific combination of strengths (eg, family support), barriers (eg, lack of insurance), and preferences (eg, preference for a certain modality or program) that might have a bearing on their treatment entry. The Navigator used motivational interviewing techniques to attempt to resolve any ambivalence about treatment and made an individualized plan regarding SUD treatment entry. If participants were willing, the Navigator would attempt to catalyze the treatment-seeking process that same day, either by calling the city's treatment referral hotline with the participant, calling a specific program (if the participant was interested in a specific modality or facility), or accompanying the participant to a nearby outpatient SUD treatment program to begin the process of enrollment.
The Patient Navigator worked with participants over the next month, delivering motivational intervention coupled with proactive barrier resolution services (Table 2) through multiple in-person visits, phone, and text contacts. Although the frequency and duration of contacts varied based on patients' needs and willingness for treatment, as a general framework the Navigator sought to have an in-person meeting with participants weekly (in addition to phone and text contacts, and communications with community providers on the participant's behalf). In-person meetings took place where convenient for participants (typically at the Navigator's office, participants' homes, public areas, or at other service providers).
Assessment
Research assessments consisted of a brief structured face-to-face interview querying substance use and related problems, medical history, and health service utilization. The interview form was specially developed for this study to rapidly assess key background and behavioral characteristics, and drew items from established instruments such as the Addiction Severity Index, 5th Edition (McLellan et al., 1992) . For medical history, items queried overnight hospitalizations and emergency department visits (lifetime, past year, and past 30 days), whether the participant currently had a primary care doctor, prior lifetime SUD treatment history, and lifetime diagnoses for HIV, hepatitis C, and sexually transmitted infections. The assessment also queried past 30-day frequency of heroin use, nonmedical use of prescription opioids, cocaine, any injection drug use, heavy alcohol use (defined as 5 or more drinks of alcohol on an occasion), unprotected sex, sex while under the influence of drugs or alcohol, and number of sex partners. A follow-up face-to-face interview was conducted at 1-month postenrollment, and focused on the same behaviors in the past 30 days, and also a series of yes/no questions about attempts to stop or cut down on drug use, and efforts for SUD treatment-seeking. Participants who did not enter SUD treatment by the follow-up point were asked how likely they were to enter treatment within the next 3 months (very unlikely, somewhat unlikely, somewhat likely, very likely). Finally, participants were asked to rate their satisfaction with Patient Navigation services (very dissatisfied, somewhat dissatisfied, somewhat satisfied, very satisfied). Participants were paid $25 for completing each assessment (regardless of whether they sought or entered treatment). No payment was provided for Patient Navigation visits. Nineteen participants completed the 1-month research follow-up (90% follow-up rate), with 2 participants unable to be located (both of these participants also could not be located for face-to-face Patient Navigation visits, although both had intermittent phone contact with the Navigator).
Analysis
Given the preliminary nature of the study and the small sample, participant characteristics and outcomes were primary summarized using descriptive statistics (eg, means, proportions). We examined change in self-reported frequency of substance use via paired t tests. For analysis purposes, we conservatively assumed that the two participants lost to follow-up had unchanged substance use from baseline (ie, last observation carried forward), and had not sought or entered SUD treatment.
RESULTS
Study 1: Screening (n U 100)
Participants were 39% female, 86% African American, 10% White, and 4% Hispanic ethnicity. The age distribution was as follows: 29%-18 to 25 years; 39%-26 to 35 years; 14%-36 to 45 years; 14%-46 to 55 years; and 4%-56 years or older. Rates of past year substance use and DSM-5 SUDs are shown in Table 3 . A majority of participants (57%) met diagnostic criteria for an alcohol and/or drug SUD, with 41% meeting SUD criteria for illicit or prescription drugs. The most common illicit drug use disorder was for cannabis, with 31% meeting criteria for cannabis use disorder. Rates of opioid and stimulant use disorders were 11% and 8%, respectively (4% met criteria for both).
Study 2: Treatment Linkage Feasibility (n U 21)
We screened 114 STD clinic patients for eligibility, of whom 25 were eligible, and 21 provided informed consent and were enrolled (13 and 8 at the West and East Baltimore sites, respectively). Only 4 eligible participants declined to participate (due to either lack of time or interest in SUD treatment). Although we did not track the number of patients who were informed about the study opportunity by clinic staff, 22% of those screened by research staff were eligible, and 84% of those who were eligible agreed to participate.
Participants were 38% female, 90% African American, and had a mean age of 42 (SD ¼ 12; age 19-59 years). The majority reported no current employment (86%). With respect to DSM-5 opioid and cocaine use disorders, 76% met diagnostic criteria for opioids, whereas 40% met criteria for cocaine. Importantly, 61% met criteria for a severe use disorder (defined as 6 or more DSM-5 criteria). Moreover, 48% had no prior SUD treatment experience. Baseline characteristics of the sample are shown in Table 4 . Table 5 summarizes contacts with the Patient Navigator over the 1-month study period. Most participants successfully engaged with the Navigator through face-to-face visits, phone conversations, and texts. By 1-month follow-up, 57% (12/21) of the sample reported attending and receiving SUD services (note: includes 1 participant who enrolled in SUD treatment within 1 week of follow-up), whereas 38% (8/21) were enrolled in SUD treatment (confirmed by program records with participants' permission). The 4 participants who received services but were not actively enrolled in SUD treatment had not yet completed admission requirements, or discontinued treatment before assessment. There were a total of 11 participants who did not enter SUD treatment and completed the follow-up assessment. When asked how likely they were to get SUD treatment in the next 3 months, 1 participant reported ''somewhat unlikely,'' whereas 10 reported ''very likely.'' Of the 19 participants who completed follow-up, 1 participant reported being ''somewhat satisfied'' with Patient Navigation services, whereas 18 reported being ''very satisfied''. Figure 1 compares past 30-day frequency of substance use at baseline versus 1-month follow-up. Although underpowered, there was a nominal reduction in self-reported frequency of substance use in the past 30 days (reduction of 32% for heroin, 26% for nonmedical prescription opioids, 83% for cocaine, and 47% for heavy alcohol use), with the reduction in cocaine use reaching statistical significance (P ¼ 0.01). All participants who completed follow-up reported attempting to stop or cut down their drug use, thinking about getting SUD treatment, and making an effort to seek SUD treatment.
DISCUSSION
This preliminary research shows feasibility of screening STD clinic patients for substance use, documents high rates of SUDs in an urban public STD clinic setting, and supports the feasibility of linking STD clinic patients with opioid and/or cocaine use disorders to SUD treatment in the community. Our findings suggest that STD clinics may tap into a substantial high-need population with SUDs, a considerable subset of which may be treatment-naïve.
Among STD clinic patients approached in the waiting room and asked to complete a private health interview, 74% agreed to participate. Rates of SUDs were high in this sample (study 1), with 35% meeting diagnostic criteria for alcohol use disorder and 41% meeting criteria for a drug use disorder. Overall, more than half of the sample met DSM-5 criteria for either alcohol or drug use disorder. These rates are considerably higher than typically found in primary care settings. For example, a study at an urban primary care clinic of a safety net hospital found that 12% of participants met alcohol use disorder criteria (Smith et al., 2009) , whereas 13% met criteria for a drug use disorder (Smith et al., 2010) . Another study conducted in primary care clinics in New York and Boston found SUD rates of 13% for alcohol and 16% for illicit drugs (McNeely et al., 2015) . A trial of initiating buprenorphine in the emergency department found rates of opioid use <2%, with still fewer opioid-dependent (D'onofrio et al., 2015) . Hence, STD clinics are a medical setting with relatively high prevalence of SUDs.
Over 1-in-10 STD clinic patients met diagnostic criteria for an opioid use disorder (either heroin or prescription opioids). Given the epidemic of opioid use disorders and overdose mortality in the United States (Dart et al., 2015; Rudd et al., 2016) , public STD clinics may be a promising medical setting in which to identify high-risk patients with opioid use disorders, link them to opioid pharmacotherapy, and provide overdose prevention education and naloxone. In recent years, prevention of opioid overdose has become a priority initiative at BCHD. As part of these efforts, clinicians at the STD clinics now provide naloxone prescriptions to patients who report opioid misuse. The integration of additional SUD services could be a logical step for STD clinics as part of a comprehensive public health approach to SUDs and the opioid use disorder epidemic.
The Treatment Linkage Feasibility study showed that recruiting STD clinic patients into this type of study was feasible and acceptable. Despite not seeking SUD services, 84% of those eligible agreed to participate in a study with the explicit goal of helping them enter SUD treatment. We consider the rate of SUD treatment entry (57% having accessed some (Yu et al., 2016) . Findings from the current pilot suggest that high rates of treatment entry can be achieved fairly quickly with SUDfocused patient navigation services. Importantly, our service model went beyond many typical referral practices or caseworker activities. Key elements included coupling motivational intervention and case management/barrier resolution, working very proactively with a small caseload towards the goal of SUD treatment entry, establishing relationships with local SUD providers, and engaging with patients in the community for several weeks after their STD clinic visit. Additional research is needed to determine if such rates of treatment entry can be sustained with wider-scale implementation, under normal service delivery conditions. In some ways, the Patient Navigation intervention reflects a model of care coordination and continuity already widely employed for HIV care. Many STD clinics are familiar with this model. Extending elements of it to address SUDs may require some creative reorganization, but could hold public health benefits. Although they typically provide episodic care, STD clinics have clinical infrastructure that could be leveraged to support various SUD services, including screening, intervention and referral, and direct initiation of SUD treatment, as done successfully with buprenorphine initiation in the emergency department, another episodic care setting (D'onofrio et al., 2015) .
The 2 studies reported in this manuscript have several important limitations. Both were conceptualized as preliminary-stage studies, with the primary purpose of informing future work to integrate substance use services into the STD clinics. Sample sizes were small. The treatment linkage study was certainly underpowered and lacked a comparison group. It is not known what the natural change in substance use or SUD treatment entry would be in the absence of intervention. Due to resource constraints, the research activities (ie, eligibility screening; assessment) and Patient Navigation services were conducted by the same staff member, which could potentially bias self-report; ideally research and service roles would be decoupled. The intervention was also time-limited, lasting only 1 month. A longer period with the Navigator may have yielded even better SUD treatment entry rates while supporting early retention and engagement (and also reengagement of patients who leave treatment prematurely). The treatment linkage study focused on patients with opioid and/or cocaine use disorders, and not the more common SUDs of alcohol and marijuana, which could be the subject of future investigation. The studies were conducted in a single city and may not generalize to all other public STD clinics. Patterns of substance use in such settings will vary based on those of the community at large, and the feasibility of SUD treatment linkage depends on local treatment system capacity.
The findings from the treatment linkage study were promising, but more research is needed to determine the feasibility and efficacy of providing such services in STD clinic settings at a larger scale and with longer follow-up. Additionally, future research should also consider service models with more complete integration of SUD services in STD clinic settings (eg, initiating buprenorphine for opioid use disorder treatment on-site, with subsequent linkage to a physician or specialty program for continued maintenance treatment). These preliminary studies support STD clinics as viable and highly promising settings for providing SUD services.
